In this work, we uncover that SETD3 likely regulates PLK1 levels directly, which might provide a combinational way through simultaneous inhibition of PLK1 activity and reduction of PLK1 transcriptional levels to deal with drug resistance of cancer cells. The gene discussed is SETD3; the disease is cancer.